A. Patel

Treatment patterns and outcomes in relapsed/refractory follicular lymphoma: results from the international SCHOLAR-5 study

J. Gribben, J. Radford, K. Deighton, 2022, Haematologica.

Clinical outcomes in patients relapsed/refractory after ≥2 prior lines of therapy for follicular lymphoma: a systematic literature review and meta-analysis

S. Kanters, B. Kahl, G. Ball, 2021, BMC Cancer.

Economic and Clinical Burden Associated with Intensification of Glaucoma Topical Therapy: A US Claims-Based Analysis.

G. Schwartz, Chi-Chang Chen, Joanna H. Campbell, 2020, Journal of glaucoma.

Approaches to Selecting “Time Zero” in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches

M. Brookhart, K. Deighton, A. Hatswell, 2022, Medical decision making : an international journal of the Society for Medical Decision Making.

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

J. Gribben, J. Radford, M. Brookhart, 2022, Blood.

Cost-effectiveness of axicabtagene ciloleucel versus lisocabtagene maraleucel for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy in the US

F. Locke, O. Oluwole, C. Feng, 2022, Journal of medical economics.

A Comparison of Clinical Outcomes from Updated Zuma-5 (Axicabtagene Ciloleucel) and the International Scholar-5 External Control Cohort in Relapsed/Refractory Follicular Lymphoma (R/R FL)

J. Gribben, J. Radford, C. Jacobson, 2021, Blood.

A 24-month updated analysis of the comparative effectiveness of ZUMA-5 (axi-cel) vs. SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

J. Gribben, J. Radford, S. Kanters, 2023, Expert review of anticancer therapy.

Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma

F. Locke, O. Oluwole, S. Keeping, 2022, Leukemia & lymphoma.

Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results.

F. Locke, O. Oluwole, A. Patel, 2024, Journal of medical economics.